To include your compound in the COVID-19 Resource Center, submit it here.

Neutralizing lupus autoantibodies

Although several classes of autoantibodies have been identified in lupus, efforts to target them have so far been unsuccessful. Now, researchers at The Feinstein Institute for Medical Research have designed a peptidomimetic small molecule that accomplished the task in mouse models of the disease.1 The researchers believe the molecule could help treat lupus nephritis as well as neuropsychiatric symptoms that occur in about a third of all lupus patients.

Moreover, the compound does not interact with immune cells, which could avoid immunosuppressive side effects that have

Read the full 856 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers